期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 56, 期 23, 页码 1908-1913出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2010.04.067
关键词
coronary heart disease; epidemiology; erectile dysfunction; stroke
资金
- Servier Laboratories
- National Health and Medical Research Council of Australia
- Medical Research Council
- Chief Scientist Office at the Scottish Government Health Directorates
- Biotechnology and Biological Sciences Research Council
- Engineering and Physical Sciences Research Council
- Economic and Social Research Council
- Institut Servier and Assistance Publique-Hopitaux de Paris
- Pfizer
- Roche
- Takeda
- Pepsico
- Amgen
- AstraZeneca
- GlaxoSmithKline
- Sanofi-Aventis
- Servier
- Tanabe
- Johnson Johnson
- Merck Schering Plough
- United Healthcare Group
- National Heart Foundation of Australia
- Dr. Reddy's laboratories
- Abbott
- Merck Frosst
- Bristol-Myers Squibb
- Novartis
- Bayer
- CIHR
- CFI
- Canada Research Center
- Genome Canada/Quebec
- Memorium
- University of Edinburgh as part of the cross-council Lifelong Health and Wellbeing initiative
- MRC [MC_U130059821] Funding Source: UKRI
- Medical Research Council [MC_U130059821] Funding Source: researchfish
Objectives The aim of this study was to examine the relationship between erectile problems in men and cardiovascular disease (CVD) mortality. Background Although there are plausible mechanisms linking erectile dysfunction (ED) with coronary heart disease (CHD) and stroke, studies are scarce. Methods In a cohort analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial population, 6,304 men age 55 to 88 years with type 2 diabetes participated in a baseline medical examination when inquiries were made about ED. Over 5 years of follow-up, during which study members attended repeat clinical examinations, the presence of fatal and nonfatal CVD outcomes, cognitive decline, and dementia was ascertained. Results After adjusting for a range of covariates, including existing illness, psychological health, and classic CVD risk factors, relative to those who were free of the condition, baseline ED was associated with an elevated risk of all CVD events (hazard ratio: 1.19; 95% confidence interval: 1.08 to 1.32), CHD (hazard ratio: 1.35; 95% confidence interval: 1.16 to 1.56), and cerebrovascular disease (hazard ratio: 1.36; 95% confidence interval: 1.11 to 1.67). Men who experienced ED at baseline and at 2-year follow-up had the highest risk for these outcomes. Conclusions In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events. (J Am Coll Cardiol 2010;56:1908-13) (C) 2010 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据